GLP1R and obesity due to melanocortin 4 receptor deficiency: For instance, in the study by Wang et al., a retrospective cohort design was employed to investigate the impact of GLP-1 receptor agonists on the incidence of 13 obesity-associated cancers in patients with type 2 diabetes [3].